Helaine I. Fingold, a Senior Counsel in the Health Care and Life Sciences practice, in the firm’s Baltimore office, and Adam C. Solander, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, were quoted in Law360, in “5 Key Takeaways from Trump’s ACA Stabilizer Rule,” by Jeff Overley. (Read the full version – subscription required.)
Following is an excerpt:
“Where’s the investment value in the long term?” asked Helaine I. Fingold, senior counsel at Epstein Becker Green. “It’s challenging to argue that it’s a good business decision to be investing in a program that it doesn’t appear has the full [support] of the administration and certainly not the Congress.” …
“It’s certainly going to discourage people from re-enrolling, and in areas where there’s not a lot of choice … it’s going to mean people are not going to be able to re-enroll,” Fingold said.